摘要
目的对胫骨骨折患者使用复方骨肽注射液进行治疗的临床效果进行探析。方法方便选取2018年8月—2020年1月该院收治的84例胫骨骨折患者作为研究对象,根据随机数字表法把患者随机分成常规组和研究组,各42例。常规组患者使用藤黄健骨片进行治疗,研究组使用复方骨肽注射液进行治疗,将两组患者治疗情况(骨生长因子、足踝功能、临床指标、术后并发症)进行分析比较。结果研究组患者并发症发生率为4.76%,骨折愈合时间为(18.00±0.52)周,消肿时间为(10.45±1.61)d,骨痂形成时间为(33.03±4.50)d;术后3、7、14 d疼痛度分别为(3.65±0.41)分、(3.01±0.22)分、(2.55±0.60)分。常规组患者并发症发生率为19.05%,骨折愈合时间为(23.21±0.52)周,消肿时间为(15.14±1.95)d,骨痂形成时间为(45.45±6.63)d;术后3、7、14 d疼痛度分别为(5.33±0.89)分、(4.99±0.75)分、(4.32±0.26)分,和常规组相比,研究组患者术后并发症更低,骨折愈合所需时间更短,消肿时间和骨痂形成时间更少,术后疼痛程度更轻,差异有统计学意义(χ^(2)=4.086,t=45.913、12.049、10.045、11.110、16.417、17.541,P<0.05)。治疗后,研究组骨形态发生蛋白、转化生长因子-β、碱性成纤维细胞因子、足踝功能分别为(142.85±15.82)pg/mL、(2692.36±326.27)pg/mL、(68.26±7.05)pg/mL、(92.75±2.32)分,均高于常规组的(110.79±19.63)pg/mL、(2117.41±303.52)pg/mL、(52.71±4.85)pg/mL、(82.41±3.58)分,差异有统计学意义(t=8.241、8.361、11.776、15.708,P<0.05)。结论为胫骨骨折患者使用复方骨肽注射液进行治疗,在骨生长因子、足踝功能方面均具有显著改善价值,且术后并发症较少,临床应用价值较高。
Objective To analyze the clinical effect of the treatment of tibia fracture patients with compound osteopeptide injection.Methods 84 patients with tibial fractures treated in the hospital from August 2018 to January 2020 were convenient selected as the research object.According to the random number table method,the patients were randomly divided into routine group and study group,with 42 cases in each group.The patients in the routine group were treated with Garcinia Gambogia Tablets,and the study group was treated with compound osteopeptide injection.The treatment conditions(bone growth factor,ankle function,clinical indicators,postoperative complications)of the two groups were analyzed and compared.Results The incidence of complications in the study group was 4.76%,the fracture healing time was(18.00±0.52)weeks,the swelling elimination time was(10.45±1.61)d,and the callus formation time was(33.03±4.50)d;the pain degrees at 3,7 and 14 d after operation were(3.65±0.41)points,(3.01±0.22)points and(2.55±0.60)points,respectively.In the routine group,the incidence of complications was 19.05%,the time of fracture healing was(23.21±0.52)weeks,the time of detumescence was(15.14±1.95)d,and the time of callus formation was(45.45±6.63)d;the pain degrees at 3,7 and 14 d after operation were(5.33±0.89)points,(4.99±0.75)points and(4.32±0.26)points,respectively.Compared with the routine group,the patients in the study group had lower postoperative complications,shorter time for fracture healing,less detumescence time and callus formation time,and less postoperative pain,the difference were statistically significant(χ^(2)=4.086,t=45.913,12.049,10.045,11.110,16.417,17.541,P<0.05).After treatment,bone morphogenetic protein and transforming growth factor-β,Basic fibroblast factor and ankle function of the study group were(142.85±15.82)pg/mL,(2692.36±326.27)pg/mL,(68.26±7.05)pg/mL and(92.75±2.32)points,respectively,which were significantly higher than those in the routine group(110.79±19.63)pg/mL,(2177.41±303.52
作者
张大伟
ZHANG Dawei(Department of Orthopedics,Second People's Hospital of Lianyungang City,Lianyungang,Jiangsu Province,222100 China)
出处
《中外医疗》
2021年第28期21-24,共4页
China & Foreign Medical Treatment
基金
江苏大学2018年度临床医学科技发展基金(JLY2018015)。
关键词
复方骨肽注射液
胫骨骨折
足踝功能
骨生长因子
Compound bone peptide injection
Tibia fracture
Foot and ankle function
Bone growth factor
